iPSC technologies scale up as new tools accelerate stem cell research and drug discovery

By Kevin Robinson | Published: 16-Mar-2026
Research & Development

New advances in large-scale iPSC production and 3D transfection technology are helping researchers to generate more diverse cell models and streamline complex stem cell workflows

You need to be a subscriber to read this article.
Click here to find out more.

Advances in induced pluripotent stem cell (iPSC) platforms and enabling technologies are continuing to reshape the landscape of drug discovery and advanced cell models, with two recent developments highlighting how scalability and experimental efficiency are improving across the sector.

US-based iXCells Biotechnologies has announced the delivery of more than 500 characterised patient-derived iPSC lines during the first year of a multi-year collaboration with a global biotechnology company. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

Read more
The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development

Trending Articles

  1. Naobios and SGS partner to manufacture RSV challenge agent for vaccine trials Naobios and SGS have partnered to produce a cGMP respiratory syncytial virus challenge agent for Controlled Human Infection Model studies, supporting faster development of vaccines against Respiratory Syncytial Virus
  2. Ananda Pharma receives MHRA and HRA approval for Phase II ENDOCAN trial in endometriosis UK biopharmaceutical company Ananda Pharma has received regulatory and ethics approval to begin a Phase II clinical trial investigating its proprietary cannabidiol (CBD) therapy for the management of endometriosis-associated pain
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    kyron.bio partners with Servier to advance precision glycosylation in antibody therapeutics The parternship will allow kyron.bio to apply its precision glycoengineering platform to antibody development. Speaking exclusively with Manufacturing Chemist, CEO of kyron.bio, Dr Emilia McLaughlin, explains the importance of the new deal
  4. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  5. Lonza As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. <br><br> Founded in Switzerland in 1897, our company is the first and original CDMO. Today, we bring together a team of 19,000 colleagues across five continents to deliver integrated offerings that meet the complex needs of our global customer community.

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development

As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Manufacturing

Why weight sorting should move earlier in OSD development

Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
Research & Development

Coriolis Pharma opens US headquarters and laboratory at Research Triangle Park in North Carolina

Biopharmaceutical services specialist Coriolis Pharma has launched its first US base at the Alexandria Centre for Advanced Technologies, offering North American clients direct access to formulation development, particle analysis and drug product characterisation services
Manufacturing

Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients

Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
Manufacturing

Naobios and SGS partner to manufacture RSV challenge agent for vaccine trials

Naobios and SGS have partnered to produce a cGMP respiratory syncytial virus challenge agent for Controlled Human Infection Model studies, supporting faster development of vaccines against Respiratory Syncytial Virus
Subscribe now